nodes	percent_of_prediction	percent_of_DWPC	metapath
Auranofin—PRDX5—Selenium Micronutrient Network—ABCA1—glaucoma	0.0122	0.028	CbGpPWpGaD
Auranofin—PRDX5—Selenium Micronutrient Network—SOD1—glaucoma	0.0108	0.0249	CbGpPWpGaD
Auranofin—Conjunctivitis—Dipivefrin—glaucoma	0.0103	0.0183	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—RPTOR—glaucoma	0.00961	0.0221	CbGpPWpGaD
Auranofin—Melaena—Methazolamide—glaucoma	0.00876	0.0155	CcSEcCtD
Auranofin—PRDX5—Selenium Micronutrient Network—MTHFR—glaucoma	0.00859	0.0198	CbGpPWpGaD
Auranofin—Aplastic anaemia—Methazolamide—glaucoma	0.00842	0.0149	CcSEcCtD
Auranofin—IKBKB—ZBP1(DAI) mediated induction of type I IFNs—TBK1—glaucoma	0.00826	0.019	CbGpPWpGaD
Auranofin—PRDX5—Cellular responses to stress—TXN—glaucoma	0.00818	0.0188	CbGpPWpGaD
Auranofin—Gastrointestinal haemorrhage—Carbachol—glaucoma	0.0069	0.0122	CcSEcCtD
Auranofin—IKBKB—p75NTR recruits signalling complexes—NGFR—glaucoma	0.0069	0.0159	CbGpPWpGaD
Auranofin—IKBKB—NF-kB is activated and signals survival—NGFR—glaucoma	0.0069	0.0159	CbGpPWpGaD
Auranofin—Gingivitis—Pilocarpine—glaucoma	0.00685	0.0121	CcSEcCtD
Auranofin—Melaena—Acetazolamide—glaucoma	0.00606	0.0107	CcSEcCtD
Auranofin—IKBKB—p75NTR signals via NF-kB—NGFR—glaucoma	0.00584	0.0134	CbGpPWpGaD
Auranofin—Glossitis—Pilocarpine—glaucoma	0.00583	0.0103	CcSEcCtD
Auranofin—Aplastic anaemia—Acetazolamide—glaucoma	0.00583	0.0103	CcSEcCtD
Auranofin—Conjunctivitis—Metipranolol—glaucoma	0.00581	0.0103	CcSEcCtD
Auranofin—Weight decreased—Diclofenamide—glaucoma	0.00553	0.00978	CcSEcCtD
Auranofin—PRDX5—Selenium Micronutrient Network—PTGS2—glaucoma	0.00548	0.0126	CbGpPWpGaD
Auranofin—Conjunctivitis—Carteolol—glaucoma	0.00538	0.00953	CcSEcCtD
Auranofin—Pancytopenia—Methazolamide—glaucoma	0.00534	0.00945	CcSEcCtD
Auranofin—IKBKB—NF-kB is activated and signals survival—NGF—glaucoma	0.00533	0.0122	CbGpPWpGaD
Auranofin—IKBKB—p75NTR recruits signalling complexes—NGF—glaucoma	0.00533	0.0122	CbGpPWpGaD
Auranofin—Melaena—Pilocarpine—glaucoma	0.00525	0.00929	CcSEcCtD
Auranofin—Visual impairment—Metipranolol—glaucoma	0.00517	0.00916	CcSEcCtD
Auranofin—IKBKB—p75(NTR)-mediated signaling—NTF4—glaucoma	0.00509	0.0117	CbGpPWpGaD
Auranofin—Conjunctivitis—Levobunolol—glaucoma	0.00509	0.00901	CcSEcCtD
Auranofin—Agranulocytosis—Diclofenamide—glaucoma	0.00508	0.009	CcSEcCtD
Auranofin—Vomiting—Physostigmine—glaucoma	0.00507	0.00898	CcSEcCtD
Auranofin—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TXNIP—glaucoma	0.00499	0.0115	CbGpPWpGaD
Auranofin—Visual impairment—Carteolol—glaucoma	0.00479	0.00848	CcSEcCtD
Auranofin—Haematuria—Methazolamide—glaucoma	0.00478	0.00846	CcSEcCtD
Auranofin—Nausea—Physostigmine—glaucoma	0.00474	0.00839	CcSEcCtD
Auranofin—Conjunctivitis—Latanoprost—glaucoma	0.00472	0.00835	CcSEcCtD
Auranofin—Agranulocytosis—Methazolamide—glaucoma	0.00468	0.00828	CcSEcCtD
Auranofin—Visual impairment—Levobunolol—glaucoma	0.00453	0.00802	CcSEcCtD
Auranofin—IKBKB—p75NTR signals via NF-kB—NGF—glaucoma	0.00451	0.0104	CbGpPWpGaD
Auranofin—PRDX5—Cellular responses to stress—SOD1—glaucoma	0.0045	0.0103	CbGpPWpGaD
Auranofin—Dermatitis exfoliative—Dorzolamide—glaucoma	0.00438	0.00774	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—CDKN2B—glaucoma	0.00426	0.00979	CbGpPWpGaD
Auranofin—Proteinuria—Betaxolol—glaucoma	0.00425	0.00753	CcSEcCtD
Auranofin—Dysgeusia—Carteolol—glaucoma	0.00424	0.0075	CcSEcCtD
Auranofin—IKBKB—TNF receptor signaling pathway —TXN—glaucoma	0.00422	0.0097	CbGpPWpGaD
Auranofin—Protein urine present—Betaxolol—glaucoma	0.00419	0.00742	CcSEcCtD
Auranofin—Alopecia—Levobunolol—glaucoma	0.00415	0.00735	CcSEcCtD
Auranofin—Dermatitis exfoliative—Pilocarpine—glaucoma	0.00413	0.00732	CcSEcCtD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—glaucoma	0.00413	0.00948	CbGpPWpGaD
Auranofin—Flatulence—Carbachol—glaucoma	0.00409	0.00725	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—IL1A—glaucoma	0.00406	0.00934	CbGpPWpGaD
Auranofin—Glossitis—Betaxolol—glaucoma	0.00405	0.00718	CcSEcCtD
Auranofin—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—TXN—glaucoma	0.00395	0.00908	CbGpPWpGaD
Auranofin—IKBKB—Cytosolic sensors of pathogen-associated DNA—TBK1—glaucoma	0.00392	0.00902	CbGpPWpGaD
Auranofin—Dysgeusia—Methazolamide—glaucoma	0.00384	0.00679	CcSEcCtD
Auranofin—Leukopenia—Diclofenamide—glaucoma	0.00381	0.00674	CcSEcCtD
Auranofin—Conjunctivitis—Apraclonidine—glaucoma	0.00377	0.00668	CcSEcCtD
Auranofin—IKBKB—mTOR signaling pathway—RPTOR—glaucoma	0.00372	0.00855	CbGpPWpGaD
Auranofin—PRDX5—Selenium Micronutrient Network—TNF—glaucoma	0.0037	0.00851	CbGpPWpGaD
Auranofin—IKBKB—Cardiac Hypertrophic Response—HDAC9—glaucoma	0.00354	0.00815	CbGpPWpGaD
Auranofin—Leukopenia—Methazolamide—glaucoma	0.00351	0.00621	CcSEcCtD
Auranofin—IKBKB—Hair Follicle Development: Induction (Part 1 of 3)—SMO—glaucoma	0.00344	0.00791	CbGpPWpGaD
Auranofin—Thrombocytopenia—Diclofenamide—glaucoma	0.0034	0.00602	CcSEcCtD
Auranofin—ALB—HDL-mediated lipid transport—ABCA1—glaucoma	0.00338	0.00776	CbGpPWpGaD
Auranofin—Dysphagia—Pilocarpine—glaucoma	0.00337	0.00597	CcSEcCtD
Auranofin—IKBKB—RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways—TBK1—glaucoma	0.00336	0.00773	CbGpPWpGaD
Auranofin—Visual impairment—Apraclonidine—glaucoma	0.00336	0.00594	CcSEcCtD
Auranofin—Anorexia—Diclofenamide—glaucoma	0.00331	0.00586	CcSEcCtD
Auranofin—Haematuria—Acetazolamide—glaucoma	0.00331	0.00586	CcSEcCtD
Auranofin—Eye disorder—Apraclonidine—glaucoma	0.00326	0.00576	CcSEcCtD
Auranofin—Visual impairment—Bimatoprost—glaucoma	0.00326	0.00576	CcSEcCtD
Auranofin—Agranulocytosis—Acetazolamide—glaucoma	0.00324	0.00573	CcSEcCtD
Auranofin—Conjunctivitis—Brimonidine—glaucoma	0.00324	0.00573	CcSEcCtD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—MYLK—glaucoma	0.00323	0.00744	CbGpPWpGaD
Auranofin—Weight decreased—Dorzolamide—glaucoma	0.00323	0.00571	CcSEcCtD
Auranofin—Eye disorder—Bimatoprost—glaucoma	0.00316	0.00559	CcSEcCtD
Auranofin—Conjunctivitis—Dorzolamide—glaucoma	0.00309	0.00547	CcSEcCtD
Auranofin—Conjunctivitis—Travoprost—glaucoma	0.00308	0.00545	CcSEcCtD
Auranofin—Dyspepsia—Diclofenamide—glaucoma	0.00306	0.00541	CcSEcCtD
Auranofin—Anorexia—Methazolamide—glaucoma	0.00305	0.0054	CcSEcCtD
Auranofin—Conjunctivitis—Brinzolamide—glaucoma	0.00304	0.00538	CcSEcCtD
Auranofin—Decreased appetite—Diclofenamide—glaucoma	0.00302	0.00534	CcSEcCtD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TBK1—glaucoma	0.00301	0.00691	CbGpPWpGaD
Auranofin—Dyspepsia—Carbachol—glaucoma	0.00298	0.00528	CcSEcCtD
Auranofin—Constipation—Diclofenamide—glaucoma	0.00297	0.00526	CcSEcCtD
Auranofin—Dysgeusia—Apraclonidine—glaucoma	0.00297	0.00526	CcSEcCtD
Auranofin—Agranulocytosis—Dorzolamide—glaucoma	0.00297	0.00526	CcSEcCtD
Auranofin—Stomatitis—Pilocarpine—glaucoma	0.00293	0.00519	CcSEcCtD
Auranofin—Conjunctivitis—Pilocarpine—glaucoma	0.00292	0.00517	CcSEcCtD
Auranofin—Visual impairment—Brimonidine—glaucoma	0.00288	0.0051	CcSEcCtD
Auranofin—Haematuria—Pilocarpine—glaucoma	0.00287	0.00507	CcSEcCtD
Auranofin—IKBKB—MyD88-independent cascade—TBK1—glaucoma	0.00284	0.00652	CbGpPWpGaD
Auranofin—IKBKB—Osteopontin Signaling—MMP9—glaucoma	0.00283	0.00651	CbGpPWpGaD
Auranofin—Dyspepsia—Methazolamide—glaucoma	0.00282	0.00498	CcSEcCtD
Auranofin—Eye disorder—Brimonidine—glaucoma	0.0028	0.00495	CcSEcCtD
Auranofin—Decreased appetite—Methazolamide—glaucoma	0.00278	0.00492	CcSEcCtD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—TBK1—glaucoma	0.00277	0.00637	CbGpPWpGaD
Auranofin—Visual impairment—Dorzolamide—glaucoma	0.00275	0.00487	CcSEcCtD
Auranofin—Visual impairment—Travoprost—glaucoma	0.00274	0.00485	CcSEcCtD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—glaucoma	0.00274	0.00629	CbGpPWpGaD
Auranofin—Visual impairment—Brinzolamide—glaucoma	0.00271	0.00479	CcSEcCtD
Auranofin—Abdominal pain—Carbachol—glaucoma	0.00268	0.00474	CcSEcCtD
Auranofin—IKBKB—IL1-mediated signaling events—IL1A—glaucoma	0.00267	0.00614	CbGpPWpGaD
Auranofin—Eye disorder—Travoprost—glaucoma	0.00266	0.0047	CcSEcCtD
Auranofin—Dysgeusia—Acetazolamide—glaucoma	0.00266	0.0047	CcSEcCtD
Auranofin—Urticaria—Levobunolol—glaucoma	0.00265	0.00469	CcSEcCtD
Auranofin—Eye disorder—Brinzolamide—glaucoma	0.00262	0.00464	CcSEcCtD
Auranofin—Visual impairment—Pilocarpine—glaucoma	0.0026	0.0046	CcSEcCtD
Auranofin—IKBKB—Activated TLR4 signalling—TBK1—glaucoma	0.00255	0.00586	CbGpPWpGaD
Auranofin—Dysgeusia—Brimonidine—glaucoma	0.00255	0.00451	CcSEcCtD
Auranofin—Urticaria—Methazolamide—glaucoma	0.00254	0.0045	CcSEcCtD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—HDAC9—glaucoma	0.00252	0.0058	CbGpPWpGaD
Auranofin—Alopecia—Dorzolamide—glaucoma	0.00252	0.00447	CcSEcCtD
Auranofin—Eye disorder—Pilocarpine—glaucoma	0.00252	0.00446	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—NTF4—glaucoma	0.0025	0.00575	CbGpPWpGaD
Auranofin—Alopecia—Brinzolamide—glaucoma	0.00248	0.00439	CcSEcCtD
Auranofin—Pruritus—Diclofenamide—glaucoma	0.00246	0.00435	CcSEcCtD
Auranofin—Dysgeusia—Dorzolamide—glaucoma	0.00243	0.00431	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—CDKN2A—glaucoma	0.00243	0.0056	CbGpPWpGaD
Auranofin—Leukopenia—Acetazolamide—glaucoma	0.00243	0.0043	CcSEcCtD
Auranofin—Dysgeusia—Travoprost—glaucoma	0.00242	0.00429	CcSEcCtD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TXN—glaucoma	0.00242	0.00557	CbGpPWpGaD
Auranofin—Flatulence—Brinzolamide—glaucoma	0.00241	0.00426	CcSEcCtD
Auranofin—Rash—Metipranolol—glaucoma	0.0024	0.00426	CcSEcCtD
Auranofin—Dermatitis—Metipranolol—glaucoma	0.0024	0.00425	CcSEcCtD
Auranofin—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—TBK1—glaucoma	0.0024	0.00552	CbGpPWpGaD
Auranofin—Dysgeusia—Brinzolamide—glaucoma	0.00239	0.00424	CcSEcCtD
Auranofin—Alopecia—Pilocarpine—glaucoma	0.00239	0.00422	CcSEcCtD
Auranofin—Pruritus—Levobunolol—glaucoma	0.00236	0.00418	CcSEcCtD
Auranofin—Dermatitis exfoliative—Timolol—glaucoma	0.00235	0.00416	CcSEcCtD
Auranofin—IKBKB—Interleukin-1 signaling—IL1A—glaucoma	0.00234	0.00539	CbGpPWpGaD
Auranofin—Dysphagia—Betaxolol—glaucoma	0.00234	0.00415	CcSEcCtD
Auranofin—IKBKB—FAS (CD95) signaling pathway—FAS—glaucoma	0.00233	0.00535	CbGpPWpGaD
Auranofin—Diarrhoea—Carbachol—glaucoma	0.00232	0.00411	CcSEcCtD
Auranofin—Flatulence—Pilocarpine—glaucoma	0.00232	0.0041	CcSEcCtD
Auranofin—Dysgeusia—Pilocarpine—glaucoma	0.0023	0.00407	CcSEcCtD
Auranofin—Diarrhoea—Levobunolol—glaucoma	0.00228	0.00404	CcSEcCtD
Auranofin—Angioedema—Dorzolamide—glaucoma	0.00227	0.00402	CcSEcCtD
Auranofin—Nausea—Metipranolol—glaucoma	0.00227	0.00401	CcSEcCtD
Auranofin—ALB—HDL-mediated lipid transport—APOE—glaucoma	0.00222	0.00511	CbGpPWpGaD
Auranofin—Vomiting—Diclofenamide—glaucoma	0.00221	0.00391	CcSEcCtD
Auranofin—Pruritus—Latanoprost—glaucoma	0.00219	0.00388	CcSEcCtD
Auranofin—Rash—Diclofenamide—glaucoma	0.00219	0.00388	CcSEcCtD
Auranofin—Diarrhoea—Methazolamide—glaucoma	0.00219	0.00387	CcSEcCtD
Auranofin—Thrombocytopenia—Acetazolamide—glaucoma	0.00217	0.00384	CcSEcCtD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TBK1—glaucoma	0.00216	0.00497	CbGpPWpGaD
Auranofin—PRDX5—Cellular responses to stress—CDKN1B—glaucoma	0.00216	0.00496	CbGpPWpGaD
Auranofin—Vomiting—Carbachol—glaucoma	0.00216	0.00382	CcSEcCtD
Auranofin—IKBKB—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.00215	0.00495	CbGpPWpGaD
Auranofin—Rash—Carbachol—glaucoma	0.00214	0.00378	CcSEcCtD
Auranofin—IKBKB—Toll-Like Receptors Cascades—TBK1—glaucoma	0.00214	0.00491	CbGpPWpGaD
Auranofin—Dermatitis—Carbachol—glaucoma	0.00214	0.00378	CcSEcCtD
Auranofin—Weight decreased—Betaxolol—glaucoma	0.00212	0.00375	CcSEcCtD
Auranofin—Constipation—Apraclonidine—glaucoma	0.00212	0.00375	CcSEcCtD
Auranofin—Dyspepsia—Bimatoprost—glaucoma	0.00211	0.00374	CcSEcCtD
Auranofin—Leukopenia—Pilocarpine—glaucoma	0.0021	0.00372	CcSEcCtD
Auranofin—Nausea—Carteolol—glaucoma	0.0021	0.00371	CcSEcCtD
Auranofin—Nausea—Diclofenamide—glaucoma	0.00206	0.00365	CcSEcCtD
Auranofin—IKBKB—Structural Pathway of Interleukin 1 (IL-1)—IL1A—glaucoma	0.00206	0.00474	CbGpPWpGaD
Auranofin—Neuropathy peripheral—Betaxolol—glaucoma	0.00205	0.00363	CcSEcCtD
Auranofin—Stomatitis—Betaxolol—glaucoma	0.00204	0.00361	CcSEcCtD
Auranofin—Vomiting—Methazolamide—glaucoma	0.00203	0.0036	CcSEcCtD
Auranofin—Conjunctivitis—Betaxolol—glaucoma	0.00203	0.0036	CcSEcCtD
Auranofin—Gastrointestinal pain—Apraclonidine—glaucoma	0.00202	0.00358	CcSEcCtD
Auranofin—Rash—Methazolamide—glaucoma	0.00202	0.00357	CcSEcCtD
Auranofin—Dermatitis—Methazolamide—glaucoma	0.00201	0.00357	CcSEcCtD
Auranofin—Eye disorder—Clonidine—glaucoma	0.00201	0.00357	CcSEcCtD
Auranofin—Nausea—Carbachol—glaucoma	0.00201	0.00356	CcSEcCtD
Auranofin—Nausea—Levobunolol—glaucoma	0.00198	0.00351	CcSEcCtD
Auranofin—Abdominal pain—Apraclonidine—glaucoma	0.00196	0.00346	CcSEcCtD
Auranofin—Rash—Latanoprost—glaucoma	0.00195	0.00346	CcSEcCtD
Auranofin—Agranulocytosis—Betaxolol—glaucoma	0.00195	0.00345	CcSEcCtD
Auranofin—Dermatitis—Latanoprost—glaucoma	0.00195	0.00345	CcSEcCtD
Auranofin—Dyspepsia—Acetazolamide—glaucoma	0.00195	0.00345	CcSEcCtD
Auranofin—ALB—Lipoprotein metabolism—ABCA1—glaucoma	0.00194	0.00446	CbGpPWpGaD
Auranofin—Anorexia—Dorzolamide—glaucoma	0.00193	0.00342	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—NCK2—glaucoma	0.00193	0.00444	CbGpPWpGaD
Auranofin—Decreased appetite—Acetazolamide—glaucoma	0.00192	0.00341	CcSEcCtD
Auranofin—Alopecia—Clonidine—glaucoma	0.0019	0.00337	CcSEcCtD
Auranofin—Nausea—Methazolamide—glaucoma	0.0019	0.00336	CcSEcCtD
Auranofin—Thrombocytopenia—Pilocarpine—glaucoma	0.00188	0.00332	CcSEcCtD
Auranofin—Dyspepsia—Brimonidine—glaucoma	0.00187	0.00331	CcSEcCtD
Auranofin—Anorexia—Pilocarpine—glaucoma	0.00183	0.00324	CcSEcCtD
Auranofin—IKBKB—IL-1 signaling pathway—IL1A—glaucoma	0.00182	0.00418	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—NGFR—glaucoma	0.00181	0.00417	CbGpPWpGaD
Auranofin—Visual impairment—Betaxolol—glaucoma	0.00181	0.0032	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—VEGFA—glaucoma	0.00179	0.00412	CbGpPWpGaD
Auranofin—Dyspepsia—Dorzolamide—glaucoma	0.00179	0.00316	CcSEcCtD
Auranofin—Dyspepsia—Travoprost—glaucoma	0.00178	0.00315	CcSEcCtD
Auranofin—Decreased appetite—Dorzolamide—glaucoma	0.00176	0.00312	CcSEcCtD
Auranofin—Urticaria—Acetazolamide—glaucoma	0.00176	0.00311	CcSEcCtD
Auranofin—Dyspepsia—Brinzolamide—glaucoma	0.00176	0.00311	CcSEcCtD
Auranofin—Eye disorder—Betaxolol—glaucoma	0.00175	0.0031	CcSEcCtD
Auranofin—Pruritus—Apraclonidine—glaucoma	0.00175	0.0031	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—SOD1—glaucoma	0.00174	0.004	CbGpPWpGaD
Auranofin—Decreased appetite—Brinzolamide—glaucoma	0.00173	0.00307	CcSEcCtD
Auranofin—Weight decreased—Timolol—glaucoma	0.00173	0.00307	CcSEcCtD
Auranofin—Constipation—Travoprost—glaucoma	0.00173	0.00306	CcSEcCtD
Auranofin—IKBKB—p75(NTR)-mediated signaling—NTRK1—glaucoma	0.00172	0.00396	CbGpPWpGaD
Auranofin—Angioedema—Clonidine—glaucoma	0.00171	0.00303	CcSEcCtD
Auranofin—IKBKB—TNF receptor signaling pathway —CAV1—glaucoma	0.0017	0.00391	CbGpPWpGaD
Auranofin—Pruritus—Bimatoprost—glaucoma	0.0017	0.003	CcSEcCtD
Auranofin—Diarrhoea—Apraclonidine—glaucoma	0.00169	0.003	CcSEcCtD
Auranofin—Dyspepsia—Pilocarpine—glaucoma	0.00169	0.00299	CcSEcCtD
Auranofin—Decreased appetite—Pilocarpine—glaucoma	0.00167	0.00295	CcSEcCtD
Auranofin—Conjunctivitis—Timolol—glaucoma	0.00166	0.00294	CcSEcCtD
Auranofin—Gastrointestinal pain—Dorzolamide—glaucoma	0.00166	0.00294	CcSEcCtD
Auranofin—Alopecia—Betaxolol—glaucoma	0.00166	0.00293	CcSEcCtD
Auranofin—Gastrointestinal pain—Travoprost—glaucoma	0.00165	0.00292	CcSEcCtD
Auranofin—IKBKB—Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways—BCL2L1—glaucoma	0.00165	0.00379	CbGpPWpGaD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—FAS—glaucoma	0.00164	0.00378	CbGpPWpGaD
Auranofin—Constipation—Pilocarpine—glaucoma	0.00164	0.0029	CcSEcCtD
Auranofin—Urticaria—Dorzolamide—glaucoma	0.00161	0.00285	CcSEcCtD
Auranofin—Abdominal pain—Dorzolamide—glaucoma	0.0016	0.00284	CcSEcCtD
Auranofin—Dysgeusia—Betaxolol—glaucoma	0.0016	0.00283	CcSEcCtD
Auranofin—Abdominal pain—Travoprost—glaucoma	0.0016	0.00283	CcSEcCtD
Auranofin—Agranulocytosis—Timolol—glaucoma	0.00159	0.00282	CcSEcCtD
Auranofin—Urticaria—Brinzolamide—glaucoma	0.00158	0.00281	CcSEcCtD
Auranofin—IKBKB—p75 NTR receptor-mediated signalling—NGFR—glaucoma	0.00158	0.00363	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—BDNF—glaucoma	0.00158	0.00363	CbGpPWpGaD
Auranofin—Vomiting—Apraclonidine—glaucoma	0.00157	0.00279	CcSEcCtD
Auranofin—Gastrointestinal pain—Pilocarpine—glaucoma	0.00157	0.00278	CcSEcCtD
Auranofin—Dermatitis—Apraclonidine—glaucoma	0.00156	0.00276	CcSEcCtD
Auranofin—Abdominal pain—Pilocarpine—glaucoma	0.00152	0.00268	CcSEcCtD
Auranofin—Diarrhoea—Acetazolamide—glaucoma	0.00151	0.00268	CcSEcCtD
Auranofin—Rash—Bimatoprost—glaucoma	0.00151	0.00268	CcSEcCtD
Auranofin—Dermatitis—Bimatoprost—glaucoma	0.00151	0.00268	CcSEcCtD
Auranofin—Anaemia—Betaxolol—glaucoma	0.00151	0.00267	CcSEcCtD
Auranofin—Pruritus—Brimonidine—glaucoma	0.0015	0.00266	CcSEcCtD
Auranofin—Thrombocytopenia—Clonidine—glaucoma	0.0015	0.00265	CcSEcCtD
Auranofin—Visual impairment—Timolol—glaucoma	0.00148	0.00261	CcSEcCtD
Auranofin—Nausea—Apraclonidine—glaucoma	0.00147	0.0026	CcSEcCtD
Auranofin—Anorexia—Clonidine—glaucoma	0.00146	0.00258	CcSEcCtD
Auranofin—Pruritus—Dorzolamide—glaucoma	0.00144	0.00254	CcSEcCtD
Auranofin—Eye disorder—Timolol—glaucoma	0.00143	0.00254	CcSEcCtD
Auranofin—IKBKB—Type II diabetes mellitus—TNF—glaucoma	0.00143	0.00329	CbGpPWpGaD
Auranofin—Pruritus—Travoprost—glaucoma	0.00143	0.00253	CcSEcCtD
Auranofin—Nausea—Bimatoprost—glaucoma	0.00143	0.00252	CcSEcCtD
Auranofin—Pruritus—Brinzolamide—glaucoma	0.00141	0.0025	CcSEcCtD
Auranofin—Vomiting—Acetazolamide—glaucoma	0.00141	0.00249	CcSEcCtD
Auranofin—IKBKB—IL-4 Signaling Pathway—BAD—glaucoma	0.00141	0.00323	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—NGF—glaucoma	0.0014	0.00322	CbGpPWpGaD
Auranofin—Diarrhoea—Dorzolamide—glaucoma	0.00139	0.00246	CcSEcCtD
Auranofin—Diarrhoea—Travoprost—glaucoma	0.00138	0.00245	CcSEcCtD
Auranofin—IKBKB—EBV LMP1 signaling—TNF—glaucoma	0.00138	0.00318	CbGpPWpGaD
Auranofin—IKBKB—Canonical NF-kappaB pathway—TNF—glaucoma	0.00138	0.00318	CbGpPWpGaD
Auranofin—Diarrhoea—Brinzolamide—glaucoma	0.00137	0.00242	CcSEcCtD
Auranofin—Pruritus—Pilocarpine—glaucoma	0.00136	0.0024	CcSEcCtD
Auranofin—PRDX5—Cellular responses to stress—TP53—glaucoma	0.00135	0.00311	CbGpPWpGaD
Auranofin—Alopecia—Timolol—glaucoma	0.00135	0.0024	CcSEcCtD
Auranofin—Rash—Brimonidine—glaucoma	0.00134	0.00237	CcSEcCtD
Auranofin—Dermatitis—Brimonidine—glaucoma	0.00134	0.00237	CcSEcCtD
Auranofin—Decreased appetite—Clonidine—glaucoma	0.00133	0.00236	CcSEcCtD
Auranofin—ALB—Selenium Micronutrient Network—TXN—glaucoma	0.00133	0.00305	CbGpPWpGaD
Auranofin—Nausea—Acetazolamide—glaucoma	0.00132	0.00233	CcSEcCtD
Auranofin—Diarrhoea—Pilocarpine—glaucoma	0.00131	0.00232	CcSEcCtD
Auranofin—Constipation—Clonidine—glaucoma	0.00131	0.00232	CcSEcCtD
Auranofin—Dysgeusia—Timolol—glaucoma	0.00131	0.00231	CcSEcCtD
Auranofin—Thrombocytopenia—Betaxolol—glaucoma	0.00131	0.00231	CcSEcCtD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—EDN1—glaucoma	0.0013	0.00299	CbGpPWpGaD
Auranofin—Vomiting—Dorzolamide—glaucoma	0.00129	0.00228	CcSEcCtD
Auranofin—ALB—Lipid and lipoprotein metabolism—ABCA1—glaucoma	0.00129	0.00296	CbGpPWpGaD
Auranofin—Rash—Dorzolamide—glaucoma	0.00128	0.00226	CcSEcCtD
Auranofin—Dermatitis—Dorzolamide—glaucoma	0.00128	0.00226	CcSEcCtD
Auranofin—ALB—Lipoprotein metabolism—APOE—glaucoma	0.00128	0.00293	CbGpPWpGaD
Auranofin—Rash—Travoprost—glaucoma	0.00127	0.00225	CcSEcCtD
Auranofin—Dermatitis—Travoprost—glaucoma	0.00127	0.00225	CcSEcCtD
Auranofin—Anorexia—Betaxolol—glaucoma	0.00127	0.00225	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—ABCA1—glaucoma	0.00127	0.00292	CbGpPWpGaD
Auranofin—Vomiting—Brinzolamide—glaucoma	0.00127	0.00225	CcSEcCtD
Auranofin—Nausea—Brimonidine—glaucoma	0.00126	0.00223	CcSEcCtD
Auranofin—Rash—Brinzolamide—glaucoma	0.00126	0.00223	CcSEcCtD
Auranofin—Dermatitis—Brinzolamide—glaucoma	0.00126	0.00222	CcSEcCtD
Auranofin—Gastrointestinal pain—Clonidine—glaucoma	0.00125	0.00222	CcSEcCtD
Auranofin—IKBKB—TCR Signaling Pathway—IL1A—glaucoma	0.00123	0.00282	CbGpPWpGaD
Auranofin—IKBKB—p75 NTR receptor-mediated signalling—NGF—glaucoma	0.00122	0.00281	CbGpPWpGaD
Auranofin—Angioedema—Timolol—glaucoma	0.00122	0.00216	CcSEcCtD
Auranofin—Vomiting—Pilocarpine—glaucoma	0.00122	0.00216	CcSEcCtD
Auranofin—Urticaria—Clonidine—glaucoma	0.00122	0.00215	CcSEcCtD
Auranofin—Abdominal pain—Clonidine—glaucoma	0.00121	0.00214	CcSEcCtD
Auranofin—Rash—Pilocarpine—glaucoma	0.00121	0.00214	CcSEcCtD
Auranofin—Dermatitis—Pilocarpine—glaucoma	0.00121	0.00214	CcSEcCtD
Auranofin—Nausea—Dorzolamide—glaucoma	0.00121	0.00213	CcSEcCtD
Auranofin—Nausea—Travoprost—glaucoma	0.0012	0.00212	CcSEcCtD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—FN1—glaucoma	0.0012	0.00275	CbGpPWpGaD
Auranofin—IKBKB—Leptin signaling pathway—BCL2L1—glaucoma	0.00119	0.00274	CbGpPWpGaD
Auranofin—Nausea—Brinzolamide—glaucoma	0.00119	0.0021	CcSEcCtD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—BAD—glaucoma	0.00118	0.00272	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—NTRK2—glaucoma	0.00117	0.0027	CbGpPWpGaD
Auranofin—Dyspepsia—Betaxolol—glaucoma	0.00117	0.00208	CcSEcCtD
Auranofin—Decreased appetite—Betaxolol—glaucoma	0.00116	0.00205	CcSEcCtD
Auranofin—IKBKB—p75(NTR)-mediated signaling—BAD—glaucoma	0.00116	0.00266	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—FAS—glaucoma	0.00115	0.00265	CbGpPWpGaD
Auranofin—Constipation—Betaxolol—glaucoma	0.00114	0.00202	CcSEcCtD
Auranofin—Nausea—Pilocarpine—glaucoma	0.00114	0.00202	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—SOD1—glaucoma	0.00113	0.0026	CbGpPWpGaD
Auranofin—IKBKB—TWEAK Signaling Pathway—MMP9—glaucoma	0.00111	0.00255	CbGpPWpGaD
Auranofin—IKBKB—Validated transcriptional targets of TAp63 isoforms—CDKN2A—glaucoma	0.00111	0.00254	CbGpPWpGaD
Auranofin—IKBKB—TCR Signaling Pathway—FAS—glaucoma	0.00109	0.00251	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—BCL2L1—glaucoma	0.00109	0.0025	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TGFB2—glaucoma	0.00109	0.0025	CbGpPWpGaD
Auranofin—Pruritus—Clonidine—glaucoma	0.00108	0.00192	CcSEcCtD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—FAS—glaucoma	0.00108	0.00249	CbGpPWpGaD
Auranofin—IKBKB—Leptin signaling pathway—BAD—glaucoma	0.00108	0.00248	CbGpPWpGaD
Auranofin—IKBKB—Signaling by Interleukins—IL1A—glaucoma	0.00106	0.00243	CbGpPWpGaD
Auranofin—Urticaria—Betaxolol—glaucoma	0.00106	0.00187	CcSEcCtD
Auranofin—IKBKB—FoxO family signaling—CDKN1B—glaucoma	0.00106	0.00243	CbGpPWpGaD
Auranofin—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—glaucoma	0.00106	0.00243	CbGpPWpGaD
Auranofin—Diarrhoea—Clonidine—glaucoma	0.00105	0.00185	CcSEcCtD
Auranofin—ALB—Platelet degranulation—TGFB2—glaucoma	0.00104	0.00239	CbGpPWpGaD
Auranofin—Anorexia—Timolol—glaucoma	0.00104	0.00184	CcSEcCtD
Auranofin—ALB—Folate Metabolism—ABCA1—glaucoma	0.00103	0.00237	CbGpPWpGaD
Auranofin—IKBKB—AGE/RAGE pathway—MMP2—glaucoma	0.00103	0.00236	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—BCL2L1—glaucoma	0.00102	0.00235	CbGpPWpGaD
Auranofin—ALB—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.00102	0.00234	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—BCL2L1—glaucoma	0.00101	0.00233	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—NGFR—glaucoma	0.00101	0.00232	CbGpPWpGaD
Auranofin—IKBKB—p75 NTR receptor-mediated signalling—BAD—glaucoma	0.00101	0.00231	CbGpPWpGaD
Auranofin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—glaucoma	0.000994	0.00228	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—glaucoma	0.000992	0.00228	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—BAD—glaucoma	0.000987	0.00227	CbGpPWpGaD
Auranofin—Vomiting—Clonidine—glaucoma	0.000974	0.00172	CcSEcCtD
Auranofin—Rash—Clonidine—glaucoma	0.000966	0.00171	CcSEcCtD
Auranofin—Dermatitis—Clonidine—glaucoma	0.000965	0.00171	CcSEcCtD
Auranofin—IKBKB—AGE/RAGE pathway—NOS3—glaucoma	0.000963	0.00221	CbGpPWpGaD
Auranofin—Dyspepsia—Timolol—glaucoma	0.000959	0.0017	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—NTRK1—glaucoma	0.000957	0.0022	CbGpPWpGaD
Auranofin—Decreased appetite—Timolol—glaucoma	0.000947	0.00168	CcSEcCtD
Auranofin—Pruritus—Betaxolol—glaucoma	0.000943	0.00167	CcSEcCtD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—BAD—glaucoma	0.000926	0.00213	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—SOD1—glaucoma	0.00092	0.00212	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—BAD—glaucoma	0.000918	0.00211	CbGpPWpGaD
Auranofin—Diarrhoea—Betaxolol—glaucoma	0.000912	0.00161	CcSEcCtD
Auranofin—Nausea—Clonidine—glaucoma	0.00091	0.00161	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—MTHFR—glaucoma	0.000897	0.00206	CbGpPWpGaD
Auranofin—Gastrointestinal pain—Timolol—glaucoma	0.000891	0.00158	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—BDNF—glaucoma	0.000876	0.00201	CbGpPWpGaD
Auranofin—IKBKB—Leptin signaling pathway—NOS3—glaucoma	0.000869	0.002	CbGpPWpGaD
Auranofin—Urticaria—Timolol—glaucoma	0.000865	0.00153	CcSEcCtD
Auranofin—Abdominal pain—Timolol—glaucoma	0.000861	0.00152	CcSEcCtD
Auranofin—IKBKB—TWEAK Signaling Pathway—TNF—glaucoma	0.000853	0.00196	CbGpPWpGaD
Auranofin—ALB—Lipid and lipoprotein metabolism—APOE—glaucoma	0.000848	0.00195	CbGpPWpGaD
Auranofin—Vomiting—Betaxolol—glaucoma	0.000848	0.0015	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—NTRK1—glaucoma	0.000846	0.00195	CbGpPWpGaD
Auranofin—Rash—Betaxolol—glaucoma	0.000841	0.00149	CcSEcCtD
Auranofin—ALB—Lipid and lipoprotein metabolism—CAV1—glaucoma	0.00084	0.00193	CbGpPWpGaD
Auranofin—Dermatitis—Betaxolol—glaucoma	0.00084	0.00149	CcSEcCtD
Auranofin—ALB—Vitamin B12 Metabolism—APOE—glaucoma	0.000835	0.00192	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—ABCA1—glaucoma	0.00082	0.00189	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CTSA—glaucoma	0.000805	0.00185	CbGpPWpGaD
Auranofin—IKBKB—TNF receptor signaling pathway —TNF—glaucoma	0.000793	0.00182	CbGpPWpGaD
Auranofin—Nausea—Betaxolol—glaucoma	0.000792	0.0014	CcSEcCtD
Auranofin—ALB—Platelet degranulation—SOD1—glaucoma	0.000789	0.00181	CbGpPWpGaD
Auranofin—IKBKB—BDNF signaling pathway—NGF—glaucoma	0.000778	0.00179	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—CDKN2A—glaucoma	0.000776	0.00178	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—BDNF—glaucoma	0.000775	0.00178	CbGpPWpGaD
Auranofin—IKBKB—AGE/RAGE pathway—MMP9—glaucoma	0.000772	0.00178	CbGpPWpGaD
Auranofin—Pruritus—Timolol—glaucoma	0.000771	0.00136	CcSEcCtD
Auranofin—ALB—Transmembrane transport of small molecules—PEX19—glaucoma	0.000766	0.00176	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—glaucoma	0.000752	0.00173	CbGpPWpGaD
Auranofin—Diarrhoea—Timolol—glaucoma	0.000745	0.00132	CcSEcCtD
Auranofin—IKBKB—MAPK Signaling Pathway—IL1A—glaucoma	0.000744	0.00171	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—SOD1—glaucoma	0.000731	0.00168	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—MTHFR—glaucoma	0.000729	0.00168	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—CDKN2A—glaucoma	0.000728	0.00167	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—TXNIP—glaucoma	0.000706	0.00162	CbGpPWpGaD
Auranofin—Vomiting—Timolol—glaucoma	0.000692	0.00123	CcSEcCtD
Auranofin—IKBKB—Innate Immune System—TBK1—glaucoma	0.000692	0.00159	CbGpPWpGaD
Auranofin—IKBKB—Cardiac Hypertrophic Response—TNF—glaucoma	0.000688	0.00158	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—NGF—glaucoma	0.000688	0.00158	CbGpPWpGaD
Auranofin—Rash—Timolol—glaucoma	0.000687	0.00122	CcSEcCtD
Auranofin—Dermatitis—Timolol—glaucoma	0.000686	0.00121	CcSEcCtD
Auranofin—ALB—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.00068	0.00156	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NTRK2—glaucoma	0.000678	0.00156	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—FAS—glaucoma	0.000663	0.00152	CbGpPWpGaD
Auranofin—Nausea—Timolol—glaucoma	0.000647	0.00114	CcSEcCtD
Auranofin—IKBKB—BDNF signaling pathway—BAD—glaucoma	0.000641	0.00147	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—C1QB—glaucoma	0.000626	0.00144	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NGFR—glaucoma	0.000582	0.00134	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—MTHFR—glaucoma	0.000579	0.00133	CbGpPWpGaD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—BAD—glaucoma	0.00057	0.00131	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—TXN—glaucoma	0.000558	0.00128	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NTRK1—glaucoma	0.000553	0.00127	CbGpPWpGaD
Auranofin—ALB—Platelet degranulation—FN1—glaucoma	0.000549	0.00126	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—BAD—glaucoma	0.000544	0.00125	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—FN1—glaucoma	0.000523	0.0012	CbGpPWpGaD
Auranofin—IKBKB—Rac1/Pak1/p38/MMP-2 pathway—TP53—glaucoma	0.000518	0.00119	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000518	0.00119	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—LRP12—glaucoma	0.000506	0.00116	CbGpPWpGaD
Auranofin—IKBKB—p75(NTR)-mediated signaling—TP53—glaucoma	0.000506	0.00116	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—BAD—glaucoma	0.000503	0.00116	CbGpPWpGaD
Auranofin—ALB—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.000497	0.00114	CbGpPWpGaD
Auranofin—IKBKB—Cytokine Signaling in Immune system—IL1A—glaucoma	0.000494	0.00114	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TNF—glaucoma	0.00049	0.00113	CbGpPWpGaD
Auranofin—IKBKB—MicroRNAs in cardiomyocyte hypertrophy—TNF—glaucoma	0.00049	0.00113	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CTSA—glaucoma	0.000488	0.00112	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000462	0.00106	CbGpPWpGaD
Auranofin—IKBKB—TNF alpha Signaling Pathway—TNF—glaucoma	0.000456	0.00105	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—NGF—glaucoma	0.000449	0.00103	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000448	0.00103	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis—TP53—glaucoma	0.000432	0.000993	CbGpPWpGaD
Auranofin—ALB—Metabolism—NARFL—glaucoma	0.000422	0.00097	CbGpPWpGaD
Auranofin—ALB—Metabolism—CA5A—glaucoma	0.000422	0.00097	CbGpPWpGaD
Auranofin—IKBKB—Toll-like Receptor Signaling Pathway—TNF—glaucoma	0.00042	0.000965	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TXNIP—glaucoma	0.000411	0.000945	CbGpPWpGaD
Auranofin—IKBKB—Apoptosis Modulation and Signaling—TP53—glaucoma	0.000405	0.000932	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TBK1—glaucoma	0.000403	0.000927	CbGpPWpGaD
Auranofin—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—glaucoma	0.000397	0.000912	CbGpPWpGaD
Auranofin—ALB—Vitamin B12 Metabolism—TNF—glaucoma	0.000386	0.000888	CbGpPWpGaD
Auranofin—IKBKB—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	0.000379	0.000871	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—BAD—glaucoma	0.00037	0.000852	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—PTGS2—glaucoma	0.00037	0.00085	CbGpPWpGaD
Auranofin—IKBKB—Immune System—C1QB—glaucoma	0.000365	0.000838	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—OPN4—glaucoma	0.000351	0.000806	CbGpPWpGaD
Auranofin—IKBKB—B Cell Activation—CDKN1B—glaucoma	0.000351	0.000806	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.00035	0.000804	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000345	0.000794	CbGpPWpGaD
Auranofin—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—glaucoma	0.000328	0.000753	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HEYL—glaucoma	0.000326	0.00075	CbGpPWpGaD
Auranofin—IKBKB—Immune System—TXN—glaucoma	0.000325	0.000747	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—PTGFR—glaucoma	0.000316	0.000726	CbGpPWpGaD
Auranofin—ALB—Platelet degranulation—VEGFA—glaucoma	0.000314	0.000722	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TNF—glaucoma	0.000314	0.000722	CbGpPWpGaD
Auranofin—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	0.000299	0.000688	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TNF—glaucoma	0.000281	0.000647	CbGpPWpGaD
Auranofin—ALB—Folate Metabolism—TP53—glaucoma	0.000277	0.000637	CbGpPWpGaD
Auranofin—IKBKB—Signaling by NGF—CDKN1B—glaucoma	0.000258	0.000593	CbGpPWpGaD
Auranofin—ALB—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000253	0.000581	CbGpPWpGaD
Auranofin—ALB—Selenium Micronutrient Network—TNF—glaucoma	0.00025	0.000574	CbGpPWpGaD
Auranofin—IKBKB—MAPK Signaling Pathway—TP53—glaucoma	0.000248	0.00057	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—RPTOR—glaucoma	0.000247	0.000568	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—C3—glaucoma	0.000244	0.00056	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—FN1—glaucoma	0.000244	0.00056	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NCK2—glaucoma	0.000239	0.00055	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TGFB2—glaucoma	0.000238	0.000547	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—C3—glaucoma	0.000234	0.000538	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—BCL2L1—glaucoma	0.000233	0.000536	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—BAD—glaucoma	0.000211	0.000486	CbGpPWpGaD
Auranofin—ALB—Metabolism—CA1—glaucoma	0.000206	0.000474	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—HDAC9—glaucoma	0.000204	0.000468	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—BAD—glaucoma	0.000203	0.000466	CbGpPWpGaD
Auranofin—ALB—Metabolism—CTSA—glaucoma	0.0002	0.000459	CbGpPWpGaD
Auranofin—ALB—Metabolism—CA2—glaucoma	0.000189	0.000433	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	0.000184	0.000424	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	0.000184	0.000424	CbGpPWpGaD
Auranofin—ALB—Hemostasis—SOD1—glaucoma	0.00018	0.000415	CbGpPWpGaD
Auranofin—IKBKB—Immune System—IL1A—glaucoma	0.000161	0.000371	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—SMO—glaucoma	0.000159	0.000366	CbGpPWpGaD
Auranofin—IKBKB—Innate Immune System—CDKN1B—glaucoma	0.000147	0.000338	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NTRK2—glaucoma	0.000146	0.000335	CbGpPWpGaD
Auranofin—IKBKB—Immune System—C3—glaucoma	0.000142	0.000326	CbGpPWpGaD
Auranofin—IKBKB—Adaptive Immune System—CDKN1B—glaucoma	0.000141	0.000325	CbGpPWpGaD
Auranofin—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	0.000139	0.00032	CbGpPWpGaD
Auranofin—ALB—Hemostasis—MMP1—glaucoma	0.000138	0.000316	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BCL2L1—glaucoma	0.000136	0.000312	CbGpPWpGaD
Auranofin—ALB—Metabolism—TXN—glaucoma	0.000133	0.000305	CbGpPWpGaD
Auranofin—ALB—Hemostasis—CAV1—glaucoma	0.000132	0.000303	CbGpPWpGaD
Auranofin—ALB—Hemostasis—FN1—glaucoma	0.000126	0.000289	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NGFR—glaucoma	0.000125	0.000287	CbGpPWpGaD
Auranofin—IKBKB—Immune System—BAD—glaucoma	0.000123	0.000283	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	0.000121	0.000279	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	0.00012	0.000276	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NTRK1—glaucoma	0.000119	0.000273	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN2B—glaucoma	0.000109	0.000252	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—EDN1—glaucoma	0.000105	0.000241	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTT1—glaucoma	0.000103	0.000237	CbGpPWpGaD
Auranofin—ALB—Hemostasis—NOS3—glaucoma	9.97e-05	0.000229	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NGF—glaucoma	9.65e-05	0.000222	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—C3—glaucoma	9.17e-05	0.000211	CbGpPWpGaD
Auranofin—IKBKB—Immune System—CDKN1B—glaucoma	8.57e-05	0.000197	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—APOE—glaucoma	8.54e-05	0.000196	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CAV1—glaucoma	8.46e-05	0.000194	CbGpPWpGaD
Auranofin—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.3e-05	0.000191	CbGpPWpGaD
Auranofin—ALB—Metabolism—ABCA1—glaucoma	8.21e-05	0.000189	CbGpPWpGaD
Auranofin—ALB—Metabolism—CYP1B1—glaucoma	8.21e-05	0.000189	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—FN1—glaucoma	8.05e-05	0.000185	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—BAD—glaucoma	7.96e-05	0.000183	CbGpPWpGaD
Auranofin—ALB—Hemostasis—VEGFA—glaucoma	7.18e-05	0.000165	CbGpPWpGaD
Auranofin—ALB—Metabolism—GSTM1—glaucoma	6.56e-05	0.000151	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—NOS3—glaucoma	6.4e-05	0.000147	CbGpPWpGaD
Auranofin—ALB—Metabolism—MTHFR—glaucoma	5.8e-05	0.000133	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—CDKN1B—glaucoma	5.54e-05	0.000127	CbGpPWpGaD
Auranofin—ALB—Hemostasis—TP53—glaucoma	5.43e-05	0.000125	CbGpPWpGaD
Auranofin—ALB—Metabolism—APOE—glaucoma	5.4e-05	0.000124	CbGpPWpGaD
Auranofin—ALB—Metabolism—CAV1—glaucoma	5.35e-05	0.000123	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—MMP9—glaucoma	5.13e-05	0.000118	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—VEGFA—glaucoma	4.61e-05	0.000106	CbGpPWpGaD
Auranofin—ALB—Metabolism—NOS3—glaucoma	4.04e-05	9.3e-05	CbGpPWpGaD
Auranofin—ALB—Metabolism—PTGS2—glaucoma	3.7e-05	8.5e-05	CbGpPWpGaD
Auranofin—IKBKB—Signaling Pathways—TP53—glaucoma	3.48e-05	8.01e-05	CbGpPWpGaD
